Cancers with disorganized 'traffic systems' more difficult to treat: research

June 21, 2012

Medical researchers at the University of Alberta reviewed test results from thousands of patients with various types of cancer and discovered that "disorganized" cancers were more difficult to treat and consistently resulted in lower survival rates.

Principal investigator Jack Tuszynski says physicians could use a , or , to determine how disorganized their patients' cancer is. Once physicians determine that, then they could pinpoint which would be the most effective. Some are effective at treating simple cancers, while others are designed to attack complex cancers.

The current emphasis in cancer treatment is to inhibit "traffic systems" in cancer, says the researcher.

"Using a math equation, doctors could predict if a given therapy will be successful, which would spare the patient from suffering," says Tuszynski, who holds the Alberta Cancer Foundation-funded Allard Research Chair in with the Faculty of Medicine & Dentistry at the University of Alberta. "Instead of spending millions of dollars on clinical trials to find better cancer drugs, algorithms could be used to better pinpoint treatment instead."

The research conducted by Tuszynski, a summer student, and research colleagues in Boston, was recently published in the peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS). The group looked at 14 , including those with high survivability, like prostate cancer, and those with high death rates, such as pancreatic cancer. Each type of cancer has its own unique "metro map," says Tuszynski.

"These traffic signalling systems inside cancer cells look like transportation hubs or metro maps, so you can measure how many stations and how many lines you have," says Tuszynski, who has a joint appointment in the Department of Oncology, as well as the Department of Physics in the Faculty of Science.

"The surprising part is, the more disorganized the traffic signalling system, the more robust and stubborn the cancer is against chemotherapy. If cancer cells have a complex metro map with lots of branches at various locations, then the cancer is very hard to paralyze.

"This research discovery has given us a glimpse into an important issue in cancer treatment. The finding is very telling."

The Alberta Cancer Foundation, which funded the research, is excited about the discovery.

"Dr. Tuszynski's work in computational biophysics promises to create more personalized treatment for cancer patients by targeting the cancerous cells while reducing side effects to healthy cells," says Myka Osinchuk, CEO of the Alberta Cancer Foundation. "This latest research discovery will help push the pace of discovery and we are excited to hear more about the progress being made in this area."

Tuszynski is continuing his research in this area and expects to soon publish more related findings.

Explore further: Some breast cancer tumors may be resistant to a common chemotherapy treatment

Related Stories

Some breast cancer tumors may be resistant to a common chemotherapy treatment

March 27, 2012
Some breast cancer tumours may be resistant to a common chemotherapy treatment, suggests recent medical research at the University of Alberta.

Cirrhosis patients losing muscle mass have a higher death rate

February 7, 2012
Medical researchers at the University of Alberta reviewed the medical records of more than 100 patients who had a liver scarring condition and discovered those who were losing muscle were more apt to die while waiting for ...

Discovery could change the way doctors treat patients with cancer and autoimmune diseases

April 27, 2011
Researchers in the Faculty of Medicine & Dentistry at the University of Alberta have made an important discovery that provides a new understanding of how our immune system "learns" not to attack our own body, and this could ...

Recommended for you

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.